Xiidra, in a 5% solution formulation, is indicated for signs and symptoms of dry eye disease in adults, and is the only prescription eye drop approved for this use. The US Food and Drug ...

Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese ... FDA approval of a phase 3 trial for eye drops containing tivanisiran, in dry eye disease associat ...